M. McGoon

发表

Diagnosis, assessment, and treatment of non-pulmonary arterial hypertension pulmonary hypertension.

F. Martinez, J. Barberà, A. Torbicki, 2009, Journal of the American College of Cardiology.

Treatment of patients with pulmonary arterial hypertension at the time of death or deterioration to functional class IV: insights from the REVEAL Registry.

Dave P. Miller, M. Mcgoon, H. Farber, 2013, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

Role of serial quantitative assessment of right ventricular function by strain in pulmonary arterial hypertension.

P. Pellikka, J. Oh, M. Mcgoon, 2013, The American journal of cardiology.

Left Ventricular Volume Changes During Dobutamine Stress Echocardiography Identify Patients with More Extensive Coronary Artery Disease

M. Enriquez-Sarano, K. Bailey, A. Tajik, 1994, Journal of the American College of Cardiology.

Validation of two predictive models for survival in pulmonary arterial hypertension

M. Humbert, R. Benza, R. Barst, 2015, European Respiratory Journal.

Chronic aortic regurgitation: indications for operation--1988.

H. Schaff, M. Mcgoon, R. Nishimura, 1988, Mayo Clinic proceedings.

The natural history of lone atrial fibrillation. A population-based study over three decades.

B. Gersh, R. Frye, J. Whisnant, 1987, The New England journal of medicine.

Right ventricular function and failure: report of a National Heart, Lung, and Blood Institute working group on cellular and molecular mechanisms of right heart failure.

M. Gladwin, C. Long, L. Leinwand, 2006, Circulation.

Aortic and mitral valve incompetence: long-term follow-up (10 to 19 years) of patients treated with the Starr-Edwards prosthesis.

V. Fuster, L. Elveback, M. Mcgoon, 1984, Journal of the American College of Cardiology.

Selection of optimal drug therapy for the patient with angina pectoris.

M. Mcgoon, C. Shub, R. Vlietstra, 1985, Mayo Clinic proceedings.

Survival in Childhood Pulmonary Arterial Hypertension: Insights From the Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management

R. Barst, M. Mcgoon, D. Ivy, 2011, Circulation.

Doppler echocardiographic index for assessment of global right ventricular function.

A J Tajik, J. Seward, K. Bailey, 1996, Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography.

Diagnosis and differential assessment of pulmonary arterial hypertension.

A. Torbicki, R. Barst, M. Mcgoon, 2004, Journal of the American College of Cardiology.

REVEAL Registry: correlation of right heart catheterization and echocardiography in patients with pulmonary arterial hypertension.

M. Mcgoon, H. Farber, Michael D McGoon, 2011, Congestive heart failure.

Valvular heart disease associated with fenfluramine-phentermine.

W. Edwards, H. Schaff, M. Mcgoon, 1997, The New England journal of medicine.

Echocardiographically documented mitral-valve prolapse. Long-term follow-up of 237 patients.

A. Tajik, M. Mcgoon, R. Nishimura, 1985, The New England journal of medicine.

Four- and seven-year outcomes of patients with congenital heart disease-associated pulmonary arterial hypertension (from the REVEAL Registry).

R. Barst, M. Mcgoon, D. Ivy, 2014, The American journal of cardiology.

Survival in Primary Pulmonary Hypertension with Long-Term Continuous Intravenous Prostacyclin

R. Barst, M. Mcgoon, L. Rubin, 1994, Annals of Internal Medicine.

Long-term outcome of patients undergoing surgical repair of isolated pulmonary valve stenosis. Follow-up at 20-30 years.

B. Gersh, M. Mcgoon, S. Kopecky, 1988, Circulation.

Screening, early detection, and diagnosis of pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines.

D. Mccrory, M. Mcgoon, J. Loyd, 2004, Chest.

A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension.

B. Groves, B. Brundage, C. Keller, 1996, The New England journal of medicine.

Primary pulmonary hypertension: natural history and the importance of thrombosis.

V. Fuster, B. Gersh, W. Edwards, 1984, Circulation.

Algorithm of Pulmonary Arterial Hypertension

W. Seeger, Z. Jing, P. Corris, 2022 .

Pulmonary Hypertension in Hereditary Hemorrhagic Telangiectasia.

M. Mcgoon, K. Swanson, R. Frantz, 2016, Chest.

Impact of pulmonary hypertension on the outcomes of noncardiac surgery: predictors of perioperative morbidity and mortality.

K. Chandrasekaran, M. Mcgoon, J. Sprung, 2005, Journal of the American College of Cardiology.

The assessment of pulmonary hypertension.

M. Mcgoon, M. McGoon, 2001, Clinics in chest medicine.

Comparison of Body Habitus in Patients With Pulmonary Arterial Hypertension Enrolled in the Registry to Evaluate Early and Long-term PAH Disease Management With Normative Values From the National Health and Nutrition Examination Survey

D. Badesch, M. Mcgoon, R. Safford, 2011 .

Pulmonary arterial hypertension: baseline characteristics from the REVEAL Registry.

G. Raskob, R. Benza, R. Barst, 2010, Chest.

Effects of Long-term Infusion of Prostacyclin (Epoprostenol) on Echocardiographic Measures of Right Ventricular Structure and Function in Primary Pulmonary Hypertension

G. Koch, B. Brundage, C. Keller, 1997 .

Right ventricular strain for prediction of survival in patients with pulmonary arterial hypertension.

P. Pellikka, J. Oh, M. Mcgoon, 2011, Chest.

Relationship of pulmonary arterial capacitance and mortality in idiopathic pulmonary arterial hypertension.

Paul Sorajja, S. Cha, M. Mcgoon, 2006, Journal of the American College of Cardiology.

Effects of long-term infusion of prostacyclin (epoprostenol) on echocardiographic measures of right ventricular structure and function in primary pulmonary hypertension. Primary Pulmonary Hypertension Study Group.

B. Groves, B. Brundage, C. Keller, 1997, Circulation.

Predicting Survival in Pulmonary Arterial Hypertension: Insights From the Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management (REVEAL)

Christopher S Coffey, C. Coffey, R. Benza, 2010, Circulation.

Relation of tissue displacement and strain to invasively determined right ventricular stroke volume.

J. Seward, K. Bailey, T. Abraham, 2005, The American journal of cardiology.

Portopulmonary hypertension: Results from a 10‐year screening algorithm

R. Wiesner, M. Mcgoon, K. Swanson, 2006, Hepatology.

Long-term outcome in patients undergoing surgical repair of tetralogy of Fallot.

V. Fuster, B. Gersh, V. Fuster, 1993, The New England journal of medicine.

Value of a Doppler-derived index combining systolic and diastolic time intervals in predicting outcome in primary pulmonary hypertension.

J B Seward, J. Seward, M. Mcgoon, 1998, The American journal of cardiology.

ACCF/AHA Expert Conseusus Document

Jeffrey L. Anderson, S. Kaul, C. Tracy, 2009 .

Disease: The Global Perspective the Developing World : Pulmonary Vascular Clinical Trials for Pulmonary Hypertension in

M. Mcgoon, J. Simon, R. Gibbs, 2010 .

The prognostic value of pulmonary vascular capacitance determined by Doppler echocardiography in patients with pulmonary arterial hypertension.

J. Oh, M. Mcgoon, R. Nishimura, 2006, Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography.

[Pulmonary arterial hypertension: epidemiology and registries].

M. Humbert, S. Rosenkranz, S. Rich, 2014, Turk Kardiyoloji Dernegi arsivi : Turk Kardiyoloji Derneginin yayin organidir.

An integrated approach to the diagnosis of pulmonary hypertension

M. Mcgoon, R. Frantz, M. McGoon, 2011 .

Breath-holding spells associated with significant bradycardia: successful treatment with permanent pacemaker implantation.

D. Hayes, M. Mcgoon, A. Kelly, 2001, Pediatrics.

Lone atrial fibrillation in elderly persons: a marker for cardiovascular risk.

B. Gersh, J. Whisnant, M. Mcgoon, 1999, Archives of internal medicine.

Pulmonary hypertension in patients with interstitial lung diseases.

P. Pellikka, M. Mcgoon, J. Ryu, 2007, Mayo Clinic proceedings.

Physician Attitudes toward Palliative Care for Patients with Pulmonary Arterial Hypertension: Results of a Cross-Sectional Survey

J. Sloan, T. Shanafelt, P. Novotny, 2014, Pulmonary circulation.

The importance of patient perspectives in pulmonary hypertension

M. Mcgoon, P. Ferrari, L. Howard, 2019, European Respiratory Journal.

Characterization of Prostacyclin‐associated Leg Pain in Patients with Pulmonary Arterial Hypertension

M. Mcgoon, K. Swetz, R. Frantz, 2017, Annals of the American Thoracic Society.

Symptom burden, quality of life, and attitudes toward palliative care in patients with pulmonary arterial hypertension: results from a cross-sectional patient survey.

Jeff A Sloan, J. Sloan, T. Shanafelt, 2012, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

An evaluation of long-term survival from time of diagnosis in pulmonary arterial hypertension from the REVEAL Registry.

R. Benza, Dave P. Miller, R. Barst, 2012, Chest.

Predicting Survival in Patients With Pulmonary Arterial Hypertension: The REVEAL Risk Score Calculator 2.0 and Comparison With ESC/ERS-Based Risk Assessment Strategies.

R. Benza, A. Frost, M. Mcgoon, 2019, Chest.

Carotid sinus hypersensitivity and syncope.

M. Mcgoon, D. Wood, D. Sugrue, 1984, Mayo Clinic proceedings.

The REVEAL Registry risk score calculator in patients newly diagnosed with pulmonary arterial hypertension.

R. Benza, D. Badesch, A. Frost, 2012, Chest.

Ambrisentan therapy for pulmonary arterial hypertension.

D. Badesch, A. Frost, M. Mcgoon, 2005, Journal of the American College of Cardiology.

Beraprost therapy for pulmonary arterial hypertension.

K. Wasserman, S. Rich, R. Barst, 2003, Journal of the American College of Cardiology.

Predicting outcomes in pulmonary arterial hypertension based on the 6-minute walk distance.

R. Benza, Dave P. Miller, A. Frost, 2015, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

Hemodynamic ranges during daily activities and exercise testing in patients with pulmonary arterial hypertension.

B. Kjellström, R. Benza, M. Mcgoon, 2014, Journal of cardiac failure.

Diagnostic dilemmas in pulmonary hypertension.

M. Mcgoon, R. Frantz, M. McGoon, 2012, Heart failure clinics.

Characterization of connective tissue disease-associated pulmonary arterial hypertension from REVEAL: identifying systemic sclerosis as a unique phenotype.

Dave P. Miller, D. Badesch, M. Mcgoon, 2010, Chest.

Analysis of the Lung Allocation Score Estimation of Risk of Death in Patients With Pulmonary Arterial Hypertension Using Data From the REVEAL Registry

R. Benza, R. Barst, A. Frost, 2010, Transplantation.

Ambrisentan for the Treatment of Pulmonary Arterial Hypertension: Results of the Ambrisentan in Pulmonary Arterial Hypertension, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Efficacy (ARIES) Study 1 and 2

B. Wiens, H. Ghofrani, D. Badesch, 2008, Circulation.

Pulmonary Arterial Hypertension

M. Mcgoon, V. McLaughlin, M. McGoon, 2006, Circulation.

Reassessing Patients Over Time : How To Follow Patients on Treatment

Jeffrey L. Anderson, S. Kaul, C. Tracy, 2009 .

McLaughlin and McGoon Pulmonary Arterial Hypertension

M. Mcgoon, V. McLaughlin, M. McGoon, 2006 .

Immediate and long-term hemodynamic and clinical effects of sildenafil in patients with pulmonary arterial hypertension receiving vasodilator therapy.

M. Mcgoon, R. Frantz, S. Bhatia, 2003, Mayo Clinic proceedings.

Diagnostic Dilemmas: Diastolic Heart Failure Causing Pulmonary Hypertension and Pulmonary Hypertension Causing Diastolic Dysfunction

M. Mcgoon, R. Nishimura, M. Redfield, 2006 .

Updated Risk Score Calculator for Pulmonary Arterial Hypertension Patients

R. Benza, A. Frost, M. Mcgoon, 2017 .

Prognostic implications of serial risk score assessments in patients with pulmonary arterial hypertension: a Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management (REVEAL) analysis.

R. Benza, Dave P. Miller, D. Badesch, 2015, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

Characterization of First-Time Hospitalizations in Patients With Newly Diagnosed Pulmonary Arterial Hypertension in the REVEAL Registry

M. Mcgoon, R. Safford, C. Burger, 2014, Chest.

Evaluation of the predictive value of a clinical worsening definition using 2-year outcomes in patients with pulmonary arterial hypertension: a REVEAL Registry analysis.

R. Benza, Dave P. Miller, D. Badesch, 2013, Chest.

Functional class improvement and 3-year survival outcomes in patients with pulmonary arterial hypertension in the REVEAL Registry.

R. Barst, M. Mcgoon, L. Chung, 2013, Chest.

Integration of clinical and hemodynamic parameters in the prediction of long-term survival in patients with pulmonary arterial hypertension.

M. Mcgoon, R. Frantz, C. Scott, 2011, Chest.

Wide variation in clinicians' assessment of New York Heart Association/World Health Organization functional class in patients with pulmonary arterial hypertension.

H. Palevsky, M. Mcgoon, D. Taichman, 2009, Mayo Clinic proceedings.

Design of the REVEAL registry for US patients with pulmonary arterial hypertension.

G. Raskob, R. Barst, M. Mcgoon, 2008, Mayo Clinic proceedings.

Cardiac sarcoidosis: a potentially treatable form of myocarditis.

W. Edwards, M. Mcgoon, R. Lemery, 1985, Mayo Clinic proceedings.

Baseline and Serial Brain Natriuretic Peptide Level Predicts 5‐Year Overall Survival in Patients With Pulmonary Arterial Hypertension: Data From the REVEAL Registry

R. Benza, D. Badesch, A. Frost, 2018, Chest.

Impact of declining renal function on outcomes in pulmonary arterial hypertension: A REVEAL registry analysis.

R. Benza, A. Frost, M. Mcgoon, 2018, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

Five-Year outcomes of patients enrolled in the REVEAL Registry.

R. Benza, Dave P. Miller, D. Badesch, 2015, Chest.

Pericardial effusions in pulmonary arterial hypertension: characteristics, prognosis, and role of drainage.

L. Sinak, J. Oh, M. Mcgoon, 2013, Chest.

Temporal trends and drug exposures in pulmonary hypertension: an American experience.

L. Abenhaim, B. Strom, S. Rich, 2006, American heart journal.

Extraction of the Telectronics Accufix 330-801 atrial lead: the Mayo Clinic experience.

D. Holmes, D. Hayes, M. Mcgoon, 1996, Mayo Clinic proceedings.

Long-term outcome after surgical repair of isolated atrial septal defect. Follow-up at 27 to 32 years.

B. Gersh, M. Mcgoon, D. Ilstrup, 1990, The New England journal of medicine.

Techniques of immunosuppression after cardiac transplantation.

M. Mcgoon, R. Frantz, M. McGoon, 1992, Mayo Clinic proceedings.

Improvement in pulmonary hemodynamics during intravenous epoprostenol (prostacyclin): A study of 15 patients with moderate to severe portopulmonary hypertension

R. Wiesner, M. Mcgoon, R. Frantz, 1999, Hepatology.

Erratum: Beraprost therapy for pulmonary arterial hypertension (Journal of the American College of Cardiology (2003) 41 (2119-2125))

K. Wasserman, S. Rich, R. Barst, 2003 .

Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial.

D. Badesch, D. Langleben, R. Bourge, 2000, Annals of internal medicine.

Continuous Intravenous Epoprostenol for Pulmonary Hypertension Due to the Scleroderma Spectrum of Disease

Stuart Rich, Srinivas Murali, C. Elliott, 2000, Annals of Internal Medicine.

Pulmonary Hypertension Care Centers

M. Mcgoon, M. Chakinala, M. McGoon, 2014 .

Chronic aortic regurgitation

H. Schaff, M. Mcgoon, R. Nishimura, 1988 .

The changing picture of patients with pulmonary arterial hypertension in the United States: how REVEAL differs from historic and non-US Contemporary Registries.

G. Raskob, R. Benza, R. Barst, 2011, Chest.

Ambrisentan therapy in patients with pulmonary arterial hypertension who discontinued bosentan or sitaxsentan due to liver function test abnormalities.

D. Badesch, A. Frost, M. Mcgoon, 2006, Chest.

Unique Predictors of Mortality in Patients With Pulmonary Arterial Hypertension Associated With Systemic Sclerosis in the REVEAL Registry

R. Benza, Dave P. Miller, M. Mcgoon, 2014, Chest.

Development of prognostic tools in pulmonary arterial hypertension: Lessons from modern day registries

M. Humbert, R. Benza, A. Frost, 2012, Thrombosis and Haemostasis.

Longterm Survival Among Patients with Scleroderma-associated Pulmonary Arterial Hypertension Treated with Intravenous Epoprostenol

D. Badesch, M. Mcgoon, V. Tapson, 2009, The Journal of Rheumatology.

Comorbid conditions and outcomes in patients with pulmonary arterial hypertension: a REVEAL registry analysis.

M. Mcgoon, H. Farber, Leslie A. Meltzer, 2013, Chest.

Unexplained pulmonary hypertension in elderly patients.

M. Mcgoon, M. Redfield, B. Shapiro, 2007, Chest.

Pulmonary arterial hypertension: epidemiology and registries.

M. Humbert, S. Rosenkranz, S. Rich, 2013, Journal of the American College of Cardiology.

Treatment of Primary Pulmonary Hypertension with Continuous Intravenous Prostacyclin (Epoprostenol): Results of a Randomized Trial

J. H. Diehl, R. Barst, M. Mcgoon, 1990 .

Treatment of primary pulmonary hypertension with continuous intravenous prostacyclin (epoprostenol). Results of a randomized trial.

L. J. Rubin, J. H. Diehl, M. McGoon, 1990, Annals of internal medicine.

Long-term ambrisentan therapy for the treatment of pulmonary arterial hypertension.

H. Ghofrani, D. Badesch, A. Frost, 2009, Journal of the American College of Cardiology.

Incidence and predictors of cardiac perforation after permanent pacemaker placement.

David L Hayes, T. Bunch, L. Sinak, 2005, Heart rhythm.

Mayo Clinic Practice of Cardiology

David L. Hayes, Bernard J. Gersh, Emilio R. Giuliani, 1996 .

Permanent cardiac pacing after the Fontan procedure.

M. Mcgoon, C. J. Porter, G. Danielson, 1985, The Journal of thoracic and cardiovascular surgery.

Long-term endocardial atrial pacing in children with postoperative bradycardia-tachycardia syndrome and limited ventricular access.

M. Mcgoon, D. McGoon, J. Maloney, 1982, The American journal of cardiology.

Efficacy and Safety of Treprostinil: An Epoprostenol Analog for Primary Pulmonary Hypertension

S. Rich, R. Barst, D. Badesch, 2003, Journal of cardiovascular pharmacology.

Vasodilator therapy for primary pulmonary hypertension.

M. Mcgoon, R. Vlietstra, M. McGoon, 1984, Mayo Clinic proceedings.

Pulmonary hypertension: diagnosis and management.

M. Mcgoon, G. Kane, Michael D. McGoon, 2009, Mayo Clinic proceedings.

Pulmonary arterial hypertension: current therapeutic strategies

M. Mcgoon, S. Kushwaha, A. Puri, 2007, Nature Clinical Practice Cardiovascular Medicine.

Pulmonary arterial hypertension: future directions: report of a National Heart, Lung and Blood Institute/Office of Rare Diseases workshop.

J. Knowles, D. Gail, S. Archer, 2004, Circulation.

Obesity drugs and the heart.

M. Mcgoon, H. Connolly, M. McGoon, 1999, Current problems in cardiology.

Impaired Left Ventricular Mechanics in Pulmonary Arterial Hypertension: Identification of a Cohort at High Risk

P. Pellikka, J. Oh, M. Mcgoon, 2013, Circulation. Heart failure.

Acute hemodynamic response to the S2-serotonergic receptor antagonist, ketanserin, in patients with primary pulmonary hypertension.

M. Mcgoon, R. Vlietstra, M. McGoon, 1987, International journal of cardiology.

The 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: a practical chronicle of progress

M. Mcgoon, O. Sitbon, E. Lau, 2015, European Respiratory Journal.

Portopulmonary hypertension: a report from the US-based REVEAL Registry.

R. Dweik, Dave P. Miller, R. Barst, 2012, Chest.

Failure of atrial natriuretic factor to increase with volume expansion in acute and chronic congestive heart failure in the dog.

M. Mcgoon, M. Redfield, J. Burnett, 1989, Circulation.

Sex differences in the diagnosis, treatment, and outcome of patients with pulmonary arterial hypertension enrolled in the registry to evaluate early and long-term pulmonary arterial hypertension disease management.

R. Barst, M. Mcgoon, S. Shapiro, 2012, Chest.

The prognostic significance of tricuspid valve regurgitation in pulmonary arterial hypertension

M. Mcgoon, R. Frantz, S. Pislaru, 2018, The clinical respiratory journal.

Beta-adrenergic blockers. Choosing among them.

M. Mcgoon, R. Vlietstra, M. McGoon, 1984, Postgraduate medicine.

Delay in recognition of pulmonary arterial hypertension: factors identified from the REVEAL Registry.

S. Halpern, Dave P. Miller, A. Frost, 2011, Chest.

Systemic thromboembolism in mitral and aortic Starr-Edwards prostheses: a 10-19 year follow-up.

V. Fuster, M. Mcgoon, J. Chesebro, 1982, Circulation.

ARIES-3: ambrisentan therapy in a diverse population of patients with pulmonary hypertension.

D. Badesch, A. Frost, M. Mcgoon, 2012, Cardiovascular therapeutics.